Genomic tests

CanCan’s feline brochure describes a targeted tumor-sequencing panel. In direct correspondence on October 13, 2026, the team confirmed that reports suggest potential treatments, but said feline evidence is very limited. Recommendations draw on human and canine oncology research, with a warning when a drug has not been tested in cats.

A potential drug target does not establish clinical benefit, a safe dose or suitability for an individual cat. The team is organizing feline safety and dosing studies with academic partners; recruiting sites and specific drugs have not been disclosed.

Official feline test brochure →

The laboratory accepts preserved tumor tissue (FFPE) or suitable fine-needle aspirate slides, with at least 30% tumor content. The brochure lists results within up to three weeks. Ask the veterinarian or pathologist to confirm sample suitability before submission.

CanCan quoted £300 / $400 in direct correspondence on October 13, 2026 and said it has patients worldwide. Confirm ordering from your country, shipping and any veterinary or pathology preparation fees with the company. These region filters describe access, not proven performance for every cancer.

This tissue test is separate from CanCan’s planned feline liquid biopsy. Treatment is selected and prescribed separately by the veterinary team.

A conference report described use in 55 dogs at one clinic. Among 45 completed tests, 37 identified potential drug options. Seven dogs had repeat blood testing; in two soft tissue sarcoma cases, the blood signal disappeared after treatment.

These are early clinical observations. Finding a possible drug target is not proof that the drug will help, and this report does not establish how reliably the test detects relapse before scans.

Study details →

Ordered through a veterinarian, with blood sent to CanCan’s laboratory in the UK. Confirm shipping, price and suitability directly. A negative result does not rule out cancer, and the test does not replace imaging or a tissue diagnosis.

In a study of 69 dogs with unclear cancer diagnoses, genomic testing helped clarify the diagnosis in 37 cases (54%). It provided treatment or prognostic information in another 22 cases.

This shows that the test can add useful information in difficult cases. It does not by itself show that following a suggested drug improves survival.

Study details →

Veterinarian-ordered genomic test. Vidium currently accepts international orders; treatment is selected and prescribed separately by the veterinary team.

This is a genomic diagnostic and treatment-guidance service, not a treatment provider. Some treatment associations rely partly on human oncology or limited canine evidence, and a genomic match does not establish clinical benefit for an individual dog.

The company reports laboratory validation of the test’s ability to detect DNA changes. That checks the measurement, rather than whether treatment chosen from the report helps dogs live longer.

Its publication list includes studies of other genomic panels. Their results cannot automatically be applied to Canine CGP, and each suggested treatment still needs its own supporting evidence.

Study details →

USA — ordered through a veterinarian or veterinary hospital. VetOmics lists the Canine CGP price as $900 to hospitals/veterinarians; the hospital may add its own markup. Treatment is separate.

This is a genomic testing and treatment-guidance service, not a treatment provider. A genomic match does not establish that a recommended therapy will work in an individual dog; canine-specific evidence is limited for some matches.

A 2025 study analyzed records of 508 dogs with splenic hemangiosarcoma. Targeted-drug treatment was associated with longer survival after surgery, and some DNA changes were linked with treatment outcomes.

Dogs were not randomly assigned to treatments, so differences between patients may explain part of the result. It does not prove that testing itself caused the benefit or that the findings apply to every cancer.

Study details →

USA — ordered and managed through the treating veterinarian/oncologist; treatment and medications are separate from testing.

This is genomic testing and treatment guidance, not a guarantee that a matched therapy will be effective. The strongest published outcome evidence is cancer-specific and should not be generalized to every tumor type.

Antech reports that CADET BRAF detects up to 85% of canine transitional cell / urothelial carcinoma cases. BRAF-PLUS can identify additional cases missed by the mutation test.

Some cancers do not carry the tested mutation, so a negative result does not rule out cancer. These are diagnostic tests, not a broad tumor DNA panel or proof that a particular drug will work.

Antech test information →

Ordered through a veterinarian using Antech's urine collection and submission instructions. Official services are listed in the USA, Canada and UK; confirm local availability, price and whether BRAF-PLUS is appropriate with the laboratory.

The result supports the veterinarian's diagnostic assessment and may be used for monitoring in confirmed cases. It does not replace the rest of the cancer workup.

LABOKLIN sequences KIT exons 8, 9 and 11. Its test information links these mutations with tumor grade and their potential value for prognosis and treatment planning.

In a prospective comparison of toceranib and vinblastine for dogs with measurable mast cell tumors, KIT mutation status did not predict treatment response. A mutation result alone cannot tell the owner whether a particular drug will help.

Study details →

Available through LABOKLIN in Europe and the UK. The laboratory requests tumor tissue preserved in formalin or embedded in paraffin. Ask the veterinarian or pathologist to confirm sample suitability, submission requirements, price and turnaround.

This test covers selected parts of one gene. It does not replace the pathology diagnosis or tumor grade, and it is not a broad genomic profile.